Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Agalsidase alfa - Takeda

Drug Profile

Agalsidase alfa - Takeda

Alternative Names: Replagal; SMP 536; TAK-675; α-galactosidase A

Latest Information Update: 27 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shire
  • Developer Endo, Inc.; Medison Pharma; Orphan Australia; Samaritan Pharmaceuticals; Sumitomo Pharma; Takeda
  • Class Galactosidases; Isoenzymes
  • Mechanism of Action Alpha-galactosidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fabry's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fabry's disease

Most Recent Events

  • 23 Apr 2024 Endo International has been acquired and merged into Endo, Inc.
  • 03 Jan 2024 Takeda completes a phase III trial in Fabry's diseases in China (IV, Infusion) (NCT04974749)
  • 06 May 2022 Phase-III clinical trials in Fabry's disease (Treatment-naive, In children, In adolescents, In adults) in China (IV) (NCT04974749)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top